

Wednesday, 19 May 2021

Pfizer Australia to distribute medicines through API

Pfizer Australia today announced the transition from its direct distribution model to a wholesaler distribution model. From 1 September 2021 API Limited (ASX:API) will distribute Pfizer Australia's portfolio of innovative and off-patent medicines to community pharmacies in a non-exclusive arrangement. This new arrangement does not include Pfizer's COVID-19 vaccine.

API's CEO and Managing Director, Richard Vincent said he very much welcomed Pfizer Australia's decision to distribute its PBS medicines through Community Service Obligation wholesalers like API.

"We are honoured that Pfizer Australia has entrusted us with the distribution of its medicines to community pharmacists and are delighted to have signed this agreement. I would particularly like to thank and acknowledge the work and cooperation of Pfizer Australia's Managing Director, Anne Harris and her team during the negotiations. We have a proud history of delivering medicines to community pharmacists for more than 100 years so I am confident that we will deliver on Pfizer Australia's trust in us," Mr Vincent said.

API said that it expects the volume provided by Pfizer Australia's agreement to deliver an estimated additional \$4 million in earnings before interest and tax (EBIT) on an annualised basis from 1 September 2021.

For further details, please refer the attached release by Pfizer Australia.

Approved for release by Richard Vincent, Managing Director and CEO

For further information:

Investors:

Carolyn Ireland API

T: +61 403 045 905

Media:

Gabriel McDowell Res Publica

T: +61 417 260 915













MEDIA RELEASE 19 May 2021

Pfizer Australia

Pfizer Australia Pty Limited 15-17, 151 Clarence St Sydney NSW 2000 Australia

ABN 50 008 422 348

Pfizer Australia transitions to wholesaler distribution model

Pfizer Australia will distribute medicines through Community Service Obligation (CSO) pharmaceutical distribution, and transition from a direct distribution model to a wholesaler distribution model in the third quarter of 2021.

Pfizer announced the decision today by signing a contract with API and expects to finalise negotiations with other wholesalers shortly.

From the end of Q3 2021, Pfizer Australia will supply its portfolio of innovative and off-patent medicines to community and hospital pharmacies in Australia via the national wholesaler model.

Pfizer is one of the world's leading biopharmaceutical companies which in Australia supplies essential medicines and vaccines to more than 5,600 community pharmacies and their patients.

Pfizer Australia & New Zealand Managing Director Anne Harris said: "Pfizer has an increased focus on innovation and R&D as a biopharmaceutical business.

"Moving from direct to wholesale distribution will enable a greater focus on our core business as a biopharmaceutical company, and better position ourselves for growth.

"Pfizer's biopharma business has a diverse product portfolio and range of sales in Australia.

"Our wholesale model will not be exclusive to one wholesaler.

"We will continue to offer next business day delivery through wholesale distribution partners, to more than 5,600 pharmacies nationally, which is virtually all pharmacies in Australia", Ms Harris said.

"From now until late Q3 2021 it will be business as usual. Pfizer's existing logistics provider will transition out as a direct distribution partner, to our pre-wholesale partner, over the coming months.

"We are committed to ensuring that patients have access to our medicines and vaccines in every location in Australia, and our direct distribution model has been a key contributor to this.

"Pfizer would like to thank DHL for their strong partnership. They have had more than 10 years of success in the direct-to-market model servicing our patients.

"We have enjoyed a long and valued relationship with DHL and remain committed to working closely with them for a smooth transition from our direct distribution partnership and ensuring continued patient access to our medicines. We will continue to partner with DHL for our pre-wholesale activities," Ms Harris said.

ENDS

Media contact:

Helen Han
Corporate Affairs
Pfizer Australia
0466 641 224 | helen.han@pfizer.com

About Pfizer Australia: Breakthroughs that change patients' lives™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes biologic and small molecule medicines and vaccines, and many of the world's best-known consumer products.

Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked in countries around the world to make a difference for all who rely on us. For more information please visit: www.pfizer.com.au

